ADTX: Aditxt Broker Consensus Forecast
This daily price chart for Aditxt (ADTX) reflects the price action of an asset currently undergoing a transition of IT contractors and financial restructuring, with the metric recorded at 0.00. The business is expanding its influence in immunology by acquiring biotech startups to create a comprehensive ecosystem. Additionally, Aditxt (ADTX) is implementing digital services with clinics to enable real-time, individualized monitoring of patient health.
Analytical breakdowns for Aditxt (ADTX)
- stock value and consensus price forecast:
- market capitalization information:
- business book valuation details:
- business debt structure and liquidity details:
Aggregate Debt to Equity Aditxt|ADTX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital aditxt.com|ADTX - Company Aggregate Debts|Debts to Book Capitalization Aditxt Corp|ADTX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Aditxt|Quick Liquidity Indicator aditxt.com
- earnings and market ratios statistics:
ADTX - Net Profit|Projected Future Earnings Aditxt|ADTX - Price to Earnings Ratio|Future Price to Earnings Multiple aditxt.com|ADTX - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Aditxt Corp|ADTX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Aditxt|ADTX - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months aditxt.com|ADTX - Net earnings per share growth this year|Earnings growth forecast for next year Aditxt
General company analysis:ADTX Aditxt Inc.
The development of the Pears platform for precision immunity monitoring in transplantation determines the fundamental value of Aditxt (ADTX) through its potential to reduce therapy toxicity. This indicator aggregates the average target prices of leading investment banks to measure the market consensus regarding the asset's fair value, allowing investors to quickly compare the current price with analysts' long-term expectations via a summary target valuation.
Competitors of Aditxt
Analyst Consensus Forecast argenx.com (ARGX)|Analyst Consensus Forecast BNTX (BioNTech)|ABVX: Broker Consensus Forecast|ADMA: Consensus Target|Protagonist Corp - Analyst Forecast Prices|IMVT (Immunovant, Inc.) - Consensus Target|Broker Consensus Forecast KNSA|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|ACRS - Analyst Consensus Forecast|KYTX: Analyst Consensus Forecast|Broker Consensus Forecast TLSA|CABA (Cabaletta Bio) - Analyst Consensus Forecast|Ventyx Biosciences Inc. (VTYX) - Analyst Median Target|Consensus Target THTX (Theratechnologies Inc)|Analyst Forecast Prices AVTX|Eledon Pharmaceuticals - Consensus Target|AGEN: Broker Consensus Forecast|CLYM: Consensus Target|zurabio.com - Analyst Forecast Prices|ATYR: Analyst Consensus Forecast|Adagene Inc. (ADAG) - Analyst Consensus Forecast|IMA (ImageneBio) - Analyst Consensus Forecast|Broker Consensus Forecast STTK (Shattuck Therapeutics)|Consensus Target EQ (Equillium, Inc.)|Analyst Forecast Prices CNTB|Immunic - Consensus Target|ATRA: Broker Consensus Forecast|IFRX - Price Target Chart|Forecast Levels Chart XFOR|ACET: Analyst Consensus Forecast|Celularity - Fair Value Consensus|INMB (INmune Bio Corp) - Analyst Consensus Forecast|Analyst Consensus Forecast Barinthus Biotherapeutics Corp|Price Target Chart Kezar Life Sciences (KZR)|SABS (sabbiotherapeutics.com) - Fair Value Consensus|Price Target Chart Akari Therapeutics Plc AKTX|ENLV - Consensus Target|Q32 Bio Corp - Analyst Consensus Forecast|GOVX - Analyst Consensus Forecast|EDSA (Edesa Biotech, Inc.) - Consensus Target|ibioinc.com - Fair Value Consensus|CARM (Carisma Therapeutics Inc) - Analyst Consensus Forecast|XTL Biopharmaceuticals Ltd (XTLB) - Analyst Median Target|Price Target Chart Bolt Biotherapeutics (BOLT)|Consensus Target hcwbiologics.com HCWB|Price Target Chart Aptevo Therapeutics Inc. APVO|AIM - Consensus Target|GRI: Consensus Target|XRTX - Analyst Consensus Forecast|ReShape Lifesciences (HIND) - Price Target Chart|Broker Consensus Forecast REVB|INDP (Indaptus Therapeutics) - Analyst Consensus Forecast|Average Forecast Price scinai.com SCNI|Analyst Consensus Forecast CALI|Analyst Consensus Forecast affimed.com (AFMD)|Analyst Consensus Forecast ALLK (Allakos)|HOOK: Broker Consensus Forecast|IGM Bio - Analyst Consensus Forecast|Analyst Median Target iteostherapeutics.com ITOS|OCEA (Ocean Biomedical) - Consensus Target|TCBP: Analyst Forecast Prices|Consensus Target THRD
